1 results about "HDAC1" patented technology

The application discloses an HDAC / PI3K dual-target inhibitor based on an imidazopyridazine parent nucleus and application thereof, and belongs to the technical field of medicinal chemistry. In view of the technical defects that existing HDAC and PI3K single-target anti-tumor drugs are prone to drug resistance, the effect on solid tumors is limited, and existing dual-target inhibitors have insufficient target activity and poor drugability, the application provides a dual-target inhibitor shown in a structural general formula (I), including pharmaceutically acceptable salts, hydrates, solvates, crystal forms, metabolites or prodrugs thereof. The compound has good inhibitory activity on HDAC1 and PI3K alpha, has excellent in-vivo and in-vitro anti-tumor activity, excellent in-vivo tumor inhibition effect and good liver and kidney safety, has a simple and mild synthesis route, is easy to be industrially produced, and can be used for preparing anti-tumor drugs, and provides a candidate scheme with novel structure and excellent drugability for clinical treatment of malignant tumors.